NUCIEN PHARMA(SH:688189)2025-04-29 16:50Financial Performance - The company's operating revenue for the third quarter was ¥35,783,445.19, a decrease of 25.93% compared to the same period last year, and a year-to-date decline of 55.32% to ¥251,110,585.69[3] - The net profit attributable to shareholders was -¥67,388,600.14 for the quarter, with a year-to-date loss of -¥57,215,916.93, representing an increase of 8,895.45% compared to the previous year[3] - Total operating revenue for the first three quarters of 2024 was CNY 251,110,585.69, a decrease of 55.32% compared to CNY 562,058,852.86 in the same period of 2023[18] - Net profit for the first three quarters of 2024 was a loss of CNY 65,925,432.36, compared to a profit of CNY 998,459.62 in the same period of 2023[20] - The basic and diluted earnings per share for the first three quarters of 2024 were both CNY -0.2089, compared to CNY 0.0024 in 2023[20] Research and Development - Research and development (R&D) expenses totaled ¥25,419,547.01 for the quarter, an increase of 49.13%, and accounted for 71.04% of operating revenue, up 35.75 percentage points[4] - The company is increasing its investment in R&D, particularly in the clinical trials for the Palivizumab inhalation solution project[8] - The company reported a significant increase in research and development expenses, totaling CNY 26,325,369.38 for the first three quarters of 2024, compared to CNY 63,925,857.68 in 2023[19] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥30,109,281.80, down 66.01% compared to the previous year[3] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 30,109,281.80, a decrease of 66.06% from CNY 88,584,510.48 in 2023[21] - The ending balance of cash and cash equivalents was $388,506,660.17, down from $561,729,383.46 at the beginning of the period[22] - The company reported a net decrease in cash and cash equivalents of -$173,222,723.29 during the period[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,069[10] - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, representing 28.57% of total shares[10] Liabilities and Equity - The company's total liabilities amounted to CNY 158,904,683.58, while total equity was CNY 1,209,656,281.13 as of the reporting date[18] - The total equity attributable to shareholders of the parent company was CNY 1,236,281,830.33, a decrease from CNY 1,303,495,883.51 in the previous year[18] Cost Management - Total operating costs for the first three quarters of 2024 were CNY 221,340,831.77, down from CNY 508,120,982.75 in 2023, reflecting a reduction of 56.47%[19] - The company reported a significant reduction in sales expenses, which were CNY 64,474,681.29 for the first three quarters of 2024, down from CNY 341,793,551.23 in 2023[19] Asset Changes - The total assets at the end of the reporting period were ¥1,368,560,964.71, a decrease of 20.40% from the previous year-end[4] - Total current assets decreased from ¥1,271,857,772.05 as of December 31, 2023, to ¥911,150,884.10 as of September 30, 2024, a decline of approximately 28.37%[13] - Cash and cash equivalents decreased from ¥665,760,897.54 to ¥389,076,108.51, a reduction of about 41.5%[13] - Accounts receivable decreased from ¥520,668,671.48 to ¥427,921,860.87, a decline of approximately 17.8%[13] - Inventory increased from ¥30,365,696.49 to ¥67,051,501.23, an increase of about 120.8%[13] - Total current liabilities decreased from ¥428,035,296.07 to ¥153,760,240.79, a reduction of about 64.0%[14] - Short-term borrowings decreased significantly from ¥322,950,113.81 to ¥65,050,555.56, a decline of approximately 79.9%[14]